Identification of S1P level and MAPK-ERK signaling in pancreatic β cells

Running title: Insulin and S1P in diabetes

Ji Hyun Park¹, Kwan Kyu Park¹, Jae Young Choe², Kyung Mi Jang³

¹Department of Pathology, College of Medicine, Catholic University of Daegu, Daegu, Korea
²Department of Emergency Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
³Department of Pediatrics, College of Medicine, Yeungnam University, Daegu, Korea

Address for correspondence: Kyung Mi Jang
Department of Pediatrics, College of Medicine, Yeungnam University, Hyeonchung-ro, Namgu, Daegu 42415, Korea
Email: fortune001j@gmail.com
https://orcid.org/0000-0002-2226-9268
Abstract

Sphingosine kinase is a lipid kinase that phosphorylates sphingosine to generate sphingosine 1-phosphate (S1P). S1P regulates pancreatic islet β-cell endoplasmic reticulum stress and proliferation. Type 1 and type 2 diabetes share some key pathogenic processes. In this study, we investigated whether secretion of insulin and production of S1P is altered in alloxan and glucose-treated cells from the rat pancreatic β-cell line RIN-5F. RIN-5F cells were treated with 2 mM alloxan and 20 mM glucose for 6 h or 24 h before being evaluated by ELISA and western blotting. Insulin secretion and expression was higher in RIN-5F cells treated with glucose compared to control cells. In contrast, alloxan treatment did not affect insulin secretion and expression in RIN-5F cells. Interestingly, compared with normal control levels, S1P/EDG-5 was increased in both alloxan and glucose treated pancreatic β cell than normal control. MAPK-ERK inhibition strongly decreased the expression of insulin and S1P in glucose- or alloxan-treated RIN-5F cells. We observe that production of S1P is increased in both diabetic cell models. In addition, MAPK-ERK signaling regulates secretion of insulin and S1P expression in pancreatic β-cells. Based on the literature and our findings, S1P may be a promising agent for the treatment of insulin-related disorders.

Keywords: Diabetes, ERK, Insulin, MAPK-ERK signaling, S1P, Sphinogolipid metabolism
Introduction

There are a number of causes of diabetes mellitus, resulting from dysfunction of β-cell insulin production and/or insulin resistance in peripheral organs. Type 1 diabetes is caused by an autoimmune assault on pancreatic β-cells, resulting in decreased insulin production. In contrast, type 2 diabetes is caused by insulin resistance. Obesity and related inflammation are known as risk factors for type 2 diabetes. Although type 1 diabetes and type 2 diabetes have different pathogenesis, secondary comorbidities such as hypertension, hyperlipidemia, nephropathy, and retinopathy can develop in patients of either type of diabetes when not controlled. Furthermore, exposure to excess lipids can cause a gradual decrease in pancreatic β-cell mass and decreased pancreatic β-cell functions such as insulin production in uncontrolled type 2 diabetes. Therefore, both type 1 and type 2 diabetes share some similar phenotypes and comorbidities.

As a potent sphingolipid mediator, sphingosine 1-phosphate (S1P) is a crucial signaling molecule that modulates a variety of cellular functions. S1P binds to S1P receptors 1-5 (transmembrane G protein-coupled receptors) to activate various intracellular and extracellular signal transduction mechanisms such as apoptosis, cell migration, differentiation, and inflammation. Elevated S1P plasma levels are known to play an important role in metabolic syndrome, and elevated S1P levels are observed in type 2 diabetic patients. In streptozotocin-induced type 1 diabetes animal models, S1P contributes to the progression of pancreatic β-cell destruction through S1P2 (sphingosine 1-phosphate receptor-2). Likewise, S1P2 is known as EDG5 (endothelial differentiation, G-protein coupled receptor 5) and EDG5 signaling is known to be associated with insulin and pancreatic β-cells. However, the molecular mechanisms of S1P have not been fully elucidated in type 1 and type 2 diabetes.
We examined the level of S1P in type 1 and type 2 experimental models of diabetes, and also tested relation between insulin signaling and S1P.

Materials and methods

1. Cell cultures and reagents

The rat pancreatic β-cell line RIN-5F was obtained from the European Collection of Animal Cell Cultures (America Type Culture Collection, CRL-11605; ATCC, VA, USA). Cells were cultured in Roswell Park Memorial Institute medium (cat. A1049101, Gibco, Gaithersburg, MD, USA) containing L-glutamine (Gibco) and supplemented with fetal bovine serum (Gibco) and an antibiotic-antimycotic mixture (Gibco). Cell cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO₂.

Sources of reagents were as follows: glucose and alloxan (Sigma-Aldrich, St. Louis, MO, USA); a specific inhibitor for ERK, PD98059 (Cell Signaling, Danvers, MA, USA); anti-S1P/EDG5, anti-pSPHK2, anti-SPHK2, anti-insulin, and anti-SREBP antibodies (Thermo Fisher Scientific, Waltham, MA, USA); anti-pERK1/2, anti-ERK1/2, anti-pAKT, anti-AKT, anti-β-actin, and horseradish peroxidase-conjugated secondary antibodies (Cell Signaling, Danvers, MA, USA). Western blots were detected using an enhanced chemiluminescence reagent (Amersham Bioscience, Amersham, UK).

2. Morphological examination

Morphological changes in cells were observed under an inverted phase-contrast microscope (Leica, Wetzlar, Germany). The effects of alloxan and glucose on pancreatic β-cells were observed for 24 h. Photographs were taken at 200× magnification using a digital camera.
3. Cytotoxicity assay

Cells were plated in 96-well culture plates at $1 \times 10^6$ cells/mL in culture medium and allowed to attach for 24 h. The medium was then discarded and replaced with fresh medium containing various concentrations of glucose or alloxan. After 24 h incubation, 10 μL of the Cell Counting Kit-8 (CCK-8, Abcam, Cambridge, MA, USA) reagent was added and culturing was continued for 1 h in a humidified atmosphere containing 5% CO$_2$. Absorbances at 450 nm were measured by a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).

4. Insulin release assays

The cell culture medium was harvested and insulin present in the supernatant was measured using human insulin enzyme linked immunosorbent assay (ELISA) (Sigma-Aldrich) and S1P (MyBioSource, San Diego, CA, USA) kits according to the manufacturers’ instructions.

5. Western blot analysis

Protein concentration was determined using a Bio-Rad Bradford kit (Bio-Rad Laboratories, CA, USA). Samples were boiled for 5 min and equal volumes were separated through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Luminescent signals were analyzed using an ImageQuant LAS 4000 Scanner (GE Healthcare, Piscataway, NJ, USA).

6. Statistical analyses
All values are expressed as mean ± standard error of the mean. Data were analyzed with GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) using Kruskal-Wallis test with Dunn’s post-hoc test for multiple comparisons. Significance was defined as $P < 0.05$.

**Results**

1. **Cytoxic effects of glucose and alloxan on RIN-5F cells**

   Before making alloxan-induced type 1 and glucose-induced type 2 cell models, we first examined their effect on the viability of RIN-5F cells. Cells were treated with glucose or alloxan for 24 h and viability was measured using the CCK-8 assay. As shown in Figure 1A, treatment of RIN-5F cells with 2 mM alloxan and 20 mM glucose reduced cell viability by 20% (Fig. 1A and B). These results were confirmed by phase-contrast microscopy. As shown in Figure 1C, control RIN-5F cells maintained in medium alone exhibited a rounded cobblestone appearance. When exposed to 2 mM alloxan and 20 mM glucose for 24 h, RIN-5F cells detached from the dish showing cell rounding, cytoplasmic blebbing, and an irregular shape. These results are consistent with the known effects of glucose and alloxan in the diabetic cell model.

2. **Production of insulin and S1P in RIN-5F cells**

   As shown in Figure 2A and B, there was no change in insulin secretion in RIN-5F cells treated with 2 mM alloxan. In contrast, insulin secretion was increased in RIN-5F cells treated with 20 mM glucose compared to control cells.

   We conducted immunoblotting and confirmed strongly increased insulin expression in RIN-5F cells treated with 20 mM glucose (Fig. 2A). In addition, the expression of S1P/EDG-5 was increased in both alloxan and glucose-treated beta cells relative to the control.
Interestingly, pSPHK2 was specifically increased in 2 mM alloxan-treated RIN-5F cells compared to the control cells and 20 mM glucose treated cells (Fig. 2B).

3. Effects of insulin signaling on S1P expression in RIN-5F cells

Mitogen-activated protein kinase (MAPK) and AKT play key roles in glucose metabolism. To identify the precise MAPK-ERK signaling pathway involved in the relationship between S1P and insulin in alloxan and glucose treated RIN-5F cells, we utilized a specific inhibitor for ERK (PD98059). Figure 3 shows that it strongly induced MAPK-ERK and reduced AKT phosphorylation in both alloxan- and glucose-treated RIN-5F cells. Interestingly, phosphorylation of MAPK-ERK was increased more strongly in alloxan- than in glucose-treated RIN-5F cells. By treating RIN-5F cells with PD98059, we confirmed that the upregulation of insulin, S1P/EDG-5 and pSPHK2 were MAPK-ERK-dependent. Specifically, PD98059 strongly inhibited the expression of insulin, S1P/EDG-5 and pSPHK2 in glucose- or alloxan-treated RIN-5F cells (Fig. 4A, B).

Discussion

Regulation of pancreatic β-cell mass affects a variety of physiological and pathological processes, such as apoptosis, autoimmunity, glucotoxicity, and insulin resistance, and is important for insulin secretion and glucose homeostasis 12). S1P is a unique bioactive lipid mediator that is generated from sphingomyelin metabolites and plays an important role in DNA synthesis, Ca^{2+} mobilization, MAPK pathway activation 13,14), and the proliferation and survival functions of islet β-cells 15).

S1P is known to regulate insulin synthesis and resistance, reduce blood glucose levels, maintain blood vessels, and decrease inflammation 16). However, the pharmacological roles of S1P in glucose metabolism remain unclear, particularly in terms of islet cell functions.

6
We used alloxan-induced type 1, and glucose-induced type 2 diabetes cell models \(^{17-20}\). Alloxan increases DNA fragmentation and inhibits glucose-stimulated insulin secretion, resulting in cell death \(^{21}\). In this study, we discovered that expression of S1P/EDG-5 was increased both in type 1 and in type 2 cell models relative to the normal control, and its level was also slightly higher in the type 1 cell model compared to the type 2 cell model (Fig. 2). Interestingly, pSPHK2 expression was not increased in glucose-induced type 2 diabetes cell models, which was like control. Recently, S1P is known to be involved in insulin secretion not only in pSPHK2 signal pathway, but also by regulating focal attachment kinase (FAK)/Src and Rho-related protein kinase (ROCK). Our results suggest that the expression of S1P in the type 2 cell model is related to FAK/Src and ROCK pathway.

AKT and ERK play important roles in regulating apoptosis of pancreatic \(\beta\)-cells \(^{22}\). In addition, the ERK pathway is involved in regulating glucose-induced insulin secretion in a \(\beta\)-cell line \(^{23}\). Our data showed that both alloxan- and glucose-treated \(\beta\)-cells exhibited significantly increased ERK phosphorylation and reduced AKT phosphorylation compared to the control. Furthermore, an ERK inhibitor significantly attenuated the increased S1P/EDG5 expression and insulin secretion in the alloxan- and glucose-treated \(\beta\)-cells. This suggests that S1P has an important role in insulin secretion associated with MAPK-ERK signaling pathway in both type 1 and type 2 cell models. Our study was limited by the fact it uses an \textit{in vitro} \(\beta\)-cell model. However, this experimental beta cell model is a kind of pilot study for future NOD mice study; other beta cell model had been reported. Numerous studies have investigated S1P and its role in diabetes and various other diseases \(^{24,25}\). One study using human \(\beta\)-cells reported that sphingolipid modulation represents a promising therapeutic route in type 1 diabetes \(^{26}\).

In conclusion, we have identified that the expression of S1P/EGF was increased in diabetes models compared to the control, moreover, the finding this study also lead us to
conclude that ERK signaling is regulated through the relationship between S1P and insulin in both type 1 and type 2 cell models. These results suggest that S1P should be considered a new treatment target for apoptosis, insulin resistance, and diabetic complications in both type 1 and type 2 diabetes.

**Conflicts of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2019R1G1A1006881). This study was presented at the 69th Conference of the Korean Pediatric Society in 2019.
References


10. Randriamboavonjy V, Badenhoop K, Schmidt H, Geisslinger G, Fisslthaler B, Fleming I. The S1P(2) receptor expressed in human platelets is linked to the RhoA


19. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes--a


Figure legends

Fig. 1. Effects of different concentrations of glucose and alloxan on viability of RIN-5F cells. (A and B) CCK reduction was calculated to measure cellular proliferation. RIN-5F cells were treated with alloxan ranging from 0.5 to 4 mM and glucose ranging from 5 to 30 mM. (C) Phase-contrast photograph of change in cellular morphology of RIN-5F cells. Magnifications 40x. The data are representative of three independent experiments and quantified as mean values ± SEM (n = 3–5). Kruskal-Wallis test with Dunn’s post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 compared to normal control.

Fig. 2. Effects of insulin and S1P production on glucose and alloxan treated RIN-5F cells. RIN-5F cells were treated with 2 mM alloxan and 20 mM glucose for 24 h. (A) The protein extract was determined using by western blot. β-actin was used to confirm equal sample loading control. (B) Western blotting was quantified by densitometric analysis. The data are representative of three independent experiments and quantified as mean values ± SEM (n = 3–5). Kruskal-Wallis test with Dunn’s post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 versus normal control; # p < 0.05, ## p < 0.01, ### p < 0.001 versus alloxan treatment group.

Fig. 3. Alloxan and glucose induced insulin signaling in RIN-5F cells. (A) Phosphorylated ERK (A) and AKT (B) were measured in RIN-5F cells treated with alloxan and glucose for 6 h. β-actin was used to confirm equal sample loading control. Western blotting was quantified by densitometric analysis. The data are representative of three independent experiments and quantified as mean values ± SEM (n = 3–5). Kruskal-Wallis test with Dunn’s post-hoc test, *
p < 0.05, ** p < 0.01, *** p < 0.001 versus normal control cells; # p < 0.05, ## p < 0.01, ### p < 0.001 versus alloxan treatment group.

Fig. 4. Inhibition of MAPK-ERK regulates alloxan and glucose induced insulin, S1P/EDG-5 and pSPHK2 expression. RIN-5F cells were pretreated with ERK inhibitor (PD98059) for 30 min and then stimulated with alloxan and glucose for 24 h. β-actin was used to confirm equal sample loading control. Western blotting was quantified by densitometric analysis. The data are representative of three independent experiments and quantified as mean values ± SEM (n = 3–5). Kruskal-Wallis test with Dunn’s post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 versus normal control cells; # p < 0.05, ## p < 0.01, ### p < 0.001 versus alloxan treatment group, #$ < 0.05, $$ p < 0.01, $$$ p < 0.001 versus glucose treatment group.
Figure 1

(A) Cell viability (%) vs. Alloxan (mM)

(B) Cell viability (%) vs. Glucose (mM)

(C) Images of NC, Alloxan, and Glucose treatments.
Figure 3

(A) pERK

<table>
<thead>
<tr>
<th>Treatment</th>
<th>pERK</th>
<th>tERK</th>
<th>βActin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alloxan (2 mM)</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Glucose (20 mM)</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

(B) pAKT

<table>
<thead>
<tr>
<th>Treatment</th>
<th>pAKT</th>
<th>tAKT</th>
<th>βActin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alloxan (2 mM)</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Glucose (20 mM)</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>